389 related articles for article (PubMed ID: 23444225)
1. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
2. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.
Warzecha CC; Sato TK; Nabet B; Hogenesch JB; Carstens RP
Mol Cell; 2009 Mar; 33(5):591-601. PubMed ID: 19285943
[TBL] [Abstract][Full Text] [Related]
3. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice.
Baraniak AP; Chen JR; Garcia-Blanco MA
Mol Cell Biol; 2006 Feb; 26(4):1209-22. PubMed ID: 16449636
[TBL] [Abstract][Full Text] [Related]
4. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
[TBL] [Abstract][Full Text] [Related]
6. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
7. PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2.
Yu-Ying C; Qian Z; Meng-Hui G; Lan F; Peng-Bo C; Gang-Qiao Z
Yi Chuan; 2024 Jan; 46(1):46-62. PubMed ID: 38230456
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.
Zhu X; Lee K; Asa SL; Ezzat S
Am J Pathol; 2007 May; 170(5):1618-28. PubMed ID: 17456767
[TBL] [Abstract][Full Text] [Related]
9. [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].
Cai TY; Zhu ZP; Xu CR; Ji X; Lv TD; Guo ZK; Lin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):628-635. PubMed ID: 35950384
[TBL] [Abstract][Full Text] [Related]
10. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.
Cha JY; Lambert QT; Reuther GW; Der CJ
Mol Cancer Res; 2008 Mar; 6(3):435-45. PubMed ID: 18337450
[TBL] [Abstract][Full Text] [Related]
11. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity.
Oltean S; Sorg BS; Albrecht T; Bonano VI; Brazas RM; Dewhirst MW; Garcia-Blanco MA
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14116-21. PubMed ID: 16963563
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
13. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
[TBL] [Abstract][Full Text] [Related]
14. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma.
Valletti A; Gigante M; Palumbo O; Carella M; Divella C; Sbisà E; Tullo A; Picardi E; D'Erchia AM; Battaglia M; Gesualdo L; Pesole G; Ranieri E
PLoS One; 2013; 8(10):e78452. PubMed ID: 24194935
[TBL] [Abstract][Full Text] [Related]
16. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.
Malouf GG; Su X; Yao H; Gao J; Xiong L; He Q; Compérat E; Couturier J; Molinié V; Escudier B; Camparo P; Doss DJ; Thompson EJ; Khayat D; Wood CG; Yu W; Teh BT; Weinstein J; Tannir NM
Clin Cancer Res; 2014 Aug; 20(15):4129-40. PubMed ID: 24899691
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.
Amann T; Bataille F; Spruss T; Dettmer K; Wild P; Liedtke C; Mühlbauer M; Kiefer P; Oefner PJ; Trautwein C; Bosserhoff AK; Hellerbrand C
Am J Pathol; 2010 Mar; 176(3):1433-42. PubMed ID: 20093481
[TBL] [Abstract][Full Text] [Related]
19. Characterization of sequences and mechanisms through which ISE/ISS-3 regulates FGFR2 splicing.
Hovhannisyan RH; Warzecha CC; Carstens RP
Nucleic Acids Res; 2006; 34(1):373-85. PubMed ID: 16410617
[TBL] [Abstract][Full Text] [Related]
20. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
